Pasar al contenido principal

DESARROLLO DE UNA PLATAFORMA DE VACUNAS CONTRA EL VIH BASADA EN PARTICULAS SIMILARES A VIRUS (VLP) ENVUELTAS Y DE ALTA DENSIDAD ANTIGENICA.

PI17/01518

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models

  • Usai, Carla
  • Ainsua-Enrich, Erola
  • Urrea Gales, Victor
  • Pradenas, Edwards
  • Lorca-Oró, Cristina
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Pérez Maíllo, Mónica
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Carabelli, Julieta
  • Trinité, Benjamin
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Izquierdo-Useros, Nuria
  • Clotet, Bonaventura
  • Blanco, Julià
  • Guallar, Victor
  • Cantero Portillo, Guillermo
  • Serra Gironella, Joan
  • Carrillo, Jorge
  • Segalés, Joaquim
AgeisassociatedwithreducedefficacyofvaccinesandlinkedtohigherriskofsevereCOVID-19.Herewe determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike glycoprotein (S-29) that had previously shown high efficacy in young animals. Thirteen to 18-month-old golden Syrian hamsters (GSH) and 22–23-month-old K18-hCAE2 mice were immunised twice with S-29 protein in AddaVaxTM adjuvant. GSH were intranasally inoculated with SARS-CoV-2 either two weeks or four months after the booster dose, while all K18-hACE2 mice were intranasally inoculated two weeks after the second immunisation. Body weight and clinical signs were recorded daily post-inoculation. Lesions and viral load were investigated in different target tissues. Immunisation induced seroconversion and production of neutralising antibodies; however, animals were only partially protected from weight loss. We observed a significant reduction in the amount of viral RNA and a faster viral protein clearance in the tissues of immunized animals. Infectious particles showed a faster decay in vaccinated animals while tissue lesion development was not altered. In GSH, the shortest interval between immunisation and inoculation reduced RNA levels in the lungs, while the longest interval was equally effective in reducing RNAinnasalturbinates; viral nucleoprotein amount decreased in both tissues. Inmice, immunisation was able to improve the survival of infected animals.Despite the high protection shown in young animals, S-29 efficacy was reduced in the geriatric population.Our research high lights the importance of testing vaccine efficacy in older animals as part of preclinical vaccine evaluation., This work was partly supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CAN was supported by predoctoral grants from Generalitat de Catalunya (2020 FI_B_0742; 2022 FI_B_00698). EPwas supportedbyadoctoralgrant from the National Agency for Research and Development of Chile (ANID: 72180406). NIU is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real-time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope and an ÄKTA Go protein purification system. Graphical abstract and drawing in Figs. 1 and 4 were created with BioRender.com., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Guallar, Victor
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Carrillo, Jorge
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18- hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development., This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452 to B.C.; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 to J.C. and SLD0016 to J.B.), the Carlos III Health Institute (PI17/ 01518 to J.B. and PI18/01332 to J.C.). J.B. is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). In addition, the project was also supported by the crowdfunding projects “YomeCorono” (to A.V., V.G., J.C., B.C., J.B. and N.I.-U.), BonPreu/Esclat, and Correos (to J.B.). CAN was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742). A.P.G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B_00698). P.A.R. was funded by a predoctoral fellowship from the Government of Catalonia (2020FI_B2_00138). E.P. was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). N.I.-U. is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021- CORONA-01 (grant 101046118). This study was also supported by CIBER—Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope, and an ÄKTA go protein purification system. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We thank to Ismael Valera, the CMCiB’s staff (Sara Capdevila, Jordi Grifols, Rosa Maria Ampudia, Jorge Diaz, Yaiza Rosales and Sergi Sunye) and the BSL3 IRTA-CReSA staff (Xavier Abad, Ivan Cordon, Anna Pou, Oscar García, Joanna Wiacek, Maria Angeles Osuna, Luís Ribas and Claudia Pereira Sunyé) for their technical assistance with in vivo animal studies., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

  • Ainsua-Enrich, Erola
  • Pedreño-Lopez, Núria
  • Bracke, Carmen
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pradenas, Edwards
  • Trinité, Benjamin
  • Marfil, Silvia
  • Miranda, Cristina
  • González, Sandra
  • Toledo, Ruth
  • Font, Marta
  • Benet, Susana
  • Escribà, Tuixent
  • Jimenez-Moyano, Esther
  • Peña, Ruth
  • Cedeño, Samandhy
  • Prado, Julia G.
  • Mothe, Beatriz
  • Brander, Christian
  • Izquierdo-Useros, Nuria
  • Serra Gironella, Joan
  • Segalés, Joaquim
  • Massanella, Marta
  • Benitez, Rosa María
  • Romero, Alba
  • Molina-Morant, Daniel
  • Blanco, Julià
  • Clotet, Bonaventura
  • Mateu, Lourdes
  • Pedro-Botet, María Luisa
  • Carrillo, Jorge
Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n = 9), common variable immunodeficiency (CVID, n = 12), combined immunodeficiency (CID, n = 1), and thymoma with immunodeficiency (TID, n = 1). unPAD patients and healthy controls (HCs, n = 10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Of interest, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+T cells. CID and TID patients developed cellular but not humoral responses. Although the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Carabelli, Julieta
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Clotet, Bonaventura
  • Guallar, Victor
  • Segalés, Joaquim
  • Carrillo, Jorge
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related. Nevertheless, S-2P still shows some molecular instability and it is produced with low yield. Here we described a novel set of mutations identified by molecular modeling and located in the S2 region of the S-2P that increase its production up to five-fold. Besides their immunogenicity, the efficacy of two representative S-2P-based mutants, S-29 and S-21, protecting from a heterologous SARS-CoV-2 Beta variant challenge was assayed in K18-hACE2 mice (an animal model of severe SARS-CoV-2 disease) and golden Syrian hamsters (GSH) (a moderate disease model). S-21 induced higher level of WH1 and Delta variants neutralizing antibodies than S-2P in K18-hACE2 mice three days after challenge. Viral load in nasal turbinate and oropharyngeal samples were reduced in S-21 and S-29 vaccinated mice. Despite that, only the S-29 protein protected 100% of K18-hACE2 mice from severe disease. When GSH were analyzed, all immunized animals were protected from disease development irrespectively of the immunogen they received. Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S- 29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/ Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CÁ-N, AP-G, and PA-R were supported by predoctoral grants from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742; 2022 FI_B_00698 and 2020FI_B2_00138, respectively). EP was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Carabelli, Julieta
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Clotet, Bonaventura
  • Guallar, Victor
  • Segalés, Joaquim
  • Carrillo, Jorge
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related. Nevertheless, S-2P still shows some molecular instability and it is produced with low yield. Here we described a novel set of mutations identified by molecular modeling and located in the S2 region of the S-2P that increase its production up to five-fold. Besides their immunogenicity, the efficacy of two representative S-2P-based mutants, S-29 and S-21, protecting from a heterologous SARS-CoV-2 Beta variant challenge was assayed in K18-hACE2 mice (an animal model of severe SARS-CoV-2 disease) and golden Syrian hamsters (GSH) (a moderate disease model). S-21 induced higher level of WH1 and Delta variants neutralizing antibodies than S-2P in K18-hACE2 mice three days after challenge. Viral load in nasal turbinate and oropharyngeal samples were reduced in S-21 and S-29 vaccinated mice. Despite that, only the S-29 protein protected 100% of K18-hACE2 mice from severe disease. When GSH were analyzed, all immunized animals were protected from disease development irrespectively of the immunogen they received. Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S- 29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/ Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CÁ-N, AP-G, and PA-R were supported by predoctoral grants from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742; 2022 FI_B_00698 and 2020FI_B2_00138, respectively). EP was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

  • Ainsua-Enrich, Erola
  • Pedreño-Lopez, Núria
  • Bracke, Carmen
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pradenas, Edwards
  • Trinité, Benjamin
  • Marfil, Silvia
  • Miranda, Cristina
  • González, Sandra
  • Toledo, Ruth
  • Font, Marta
  • Benet, Susana
  • Escribà, Tuixent
  • Jimenez-Moyano, Esther
  • Peña, Ruth
  • Cedeño, Samandhy
  • Prado, Julia G.
  • Mothe, Beatriz
  • Brander, Christian
  • Izquierdo-Useros, Nuria
  • Serra Gironella, Joan
  • Segalés, Joaquim
  • Massanella, Marta
  • Benitez, Rosa María
  • Romero, Alba
  • Molina-Morant, Daniel
  • Blanco, Julià
  • Clotet, Bonaventura
  • Mateu, Lourdes
  • Pedro-Botet, María Luisa
  • Carrillo, Jorge
Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n = 9), common variable immunodeficiency (CVID, n = 12), combined immunodeficiency (CID, n = 1), and thymoma with immunodeficiency (TID, n = 1). unPAD patients and healthy controls (HCs, n = 10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Of interest, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+T cells. CID and TID patients developed cellular but not humoral responses. Although the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models

  • Usai, Carla
  • Ainsua-Enrich, Erola
  • Urrea Gales, Victor
  • Pradenas, Edwards
  • Lorca-Oró, Cristina
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Pérez Maíllo, Mónica
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Carabelli, Julieta
  • Trinité, Benjamin
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Izquierdo-Useros, Nuria
  • Clotet, Bonaventura
  • Blanco, Julià
  • Guallar, Victor
  • Cantero Portillo, Guillermo
  • Serra Gironella, Joan
  • Carrillo, Jorge
  • Segalés, Joaquim
AgeisassociatedwithreducedefficacyofvaccinesandlinkedtohigherriskofsevereCOVID-19.Herewe determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike glycoprotein (S-29) that had previously shown high efficacy in young animals. Thirteen to 18-month-old golden Syrian hamsters (GSH) and 22–23-month-old K18-hCAE2 mice were immunised twice with S-29 protein in AddaVaxTM adjuvant. GSH were intranasally inoculated with SARS-CoV-2 either two weeks or four months after the booster dose, while all K18-hACE2 mice were intranasally inoculated two weeks after the second immunisation. Body weight and clinical signs were recorded daily post-inoculation. Lesions and viral load were investigated in different target tissues. Immunisation induced seroconversion and production of neutralising antibodies; however, animals were only partially protected from weight loss. We observed a significant reduction in the amount of viral RNA and a faster viral protein clearance in the tissues of immunized animals. Infectious particles showed a faster decay in vaccinated animals while tissue lesion development was not altered. In GSH, the shortest interval between immunisation and inoculation reduced RNA levels in the lungs, while the longest interval was equally effective in reducing RNAinnasalturbinates; viral nucleoprotein amount decreased in both tissues. Inmice, immunisation was able to improve the survival of infected animals.Despite the high protection shown in young animals, S-29 efficacy was reduced in the geriatric population.Our research high lights the importance of testing vaccine efficacy in older animals as part of preclinical vaccine evaluation., This work was partly supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CAN was supported by predoctoral grants from Generalitat de Catalunya (2020 FI_B_0742; 2022 FI_B_00698). EPwas supportedbyadoctoralgrant from the National Agency for Research and Development of Chile (ANID: 72180406). NIU is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real-time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope and an ÄKTA Go protein purification system. Graphical abstract and drawing in Figs. 1 and 4 were created with BioRender.com., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Guallar, Victor
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Carrillo, Jorge
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18- hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development., This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452 to B.C.; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 to J.C. and SLD0016 to J.B.), the Carlos III Health Institute (PI17/ 01518 to J.B. and PI18/01332 to J.C.). J.B. is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). In addition, the project was also supported by the crowdfunding projects “YomeCorono” (to A.V., V.G., J.C., B.C., J.B. and N.I.-U.), BonPreu/Esclat, and Correos (to J.B.). CAN was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742). A.P.G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B_00698). P.A.R. was funded by a predoctoral fellowship from the Government of Catalonia (2020FI_B2_00138). E.P. was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). N.I.-U. is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021- CORONA-01 (grant 101046118). This study was also supported by CIBER—Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope, and an ÄKTA go protein purification system. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We thank to Ismael Valera, the CMCiB’s staff (Sara Capdevila, Jordi Grifols, Rosa Maria Ampudia, Jorge Diaz, Yaiza Rosales and Sergi Sunye) and the BSL3 IRTA-CReSA staff (Xavier Abad, Ivan Cordon, Anna Pou, Oscar García, Joanna Wiacek, Maria Angeles Osuna, Luís Ribas and Claudia Pereira Sunyé) for their technical assistance with in vivo animal studies., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

  • Trinité, Benjamin|||0000-0003-3809-042X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Rodon, Jordi|||0000-0002-1032-9091
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Urrea, Víctor|||0000-0002-2577-856X
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Avila-Nieto, Carlos
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Paredes, Roger|||0000-0002-6553-691X
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Guallar, Victor|||0000-0002-4580-1114
  • Ruiz, Lidia
  • Grau, Eulàlia|||0000-0002-2442-9165
  • Massanella, Marta|||0000-0002-3326-151X
  • Puig, Jordi|||0000-0002-4075-0346
  • Chamorro, Anna
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Blanco, Julià|||0000-0002-2225-0217
The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody responses and their association with disease severity. Between March and May 2020, the prospective KING study enrolled 72 COVID-19+ participants grouped according to disease severity. SARS-CoV-2 infection was diagnosed by serological and virological tests. Plasma neutralizing responses were assessed against replicative virus and pseudoviral particles. Multiple regression and non-parametric tests were used to analyze dependence of parameters. The magnitude of neutralizing titers significantly increased with disease severity. Hospitalized individuals developed higher titers compared to mild-symptomatic and asymptomatic individuals, which together showed titers below the detection limit in 50% of cases. Longitudinal analysis confirmed the strong differences in neutralizing titers between non-hospitalized and hospitalized participants and showed rapid kinetics of appearance of neutralizing antibodies (50% and 80% of maximal activity reached after 11 and 17 days after symptoms onset, respectively) in hospitalized patients. No significant impact of age, gender or treatment on the neutralizing titers was observed in this limited cohort. These data identify a clear association of humoral immunity with disease severity and point to immune mechanisms other than antibodies as relevant players in COVID-19 protection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals

  • Trinité, Benjamin|||0000-0003-3809-042X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Urrea, Víctor|||0000-0002-2577-856X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Rodon, Jordi|||0000-0002-1032-9091
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Guallar, Victor|||0000-0002-4580-1114
  • Lepore, Rosalba
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Trujillo, Glòria
  • Trapé, Jaume
  • González-Fernández, Carolina
  • Flor, Antonia
  • Pérez-Vidal, Rafel
  • Toledo, Ruth
  • Chamorro, Anna
  • Paredes, Roger|||0000-0002-6553-691X
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Grau, Eulàlia|||0000-0002-2442-9165
  • Massanella, Marta|||0000-0002-3326-151X
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
With the spread of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a need to assess the protection conferred by both previous infections and current vaccination. Here we tested the neutralizing activity of infected and/or vaccinated individuals against pseudoviruses expressing the spike of the original SARS-CoV-2 isolate Wuhan-Hu-1 (WH1), the D614G mutant and the B.1.1.7 variant. Our data show that parameters of natural infection (time from infection and nature of the infecting variant) determined cross-neutralization. Uninfected vaccinees showed a small reduction in neutralization against the B.1.1.7 variant compared to both the WH1 strain and the D614G mutant. Interestingly, upon vaccination, previously infected individuals developed more robust neutralizing responses against B.1.1.7, suggesting that vaccines can boost the neutralization breadth conferred by natural infection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

  • Pradenas, Edwards|||0000-0001-5162-8920
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Urrea, Víctor|||0000-0002-2577-856X
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Rodon, Jordi|||0000-0002-1032-9091
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Guallar, Victor|||0000-0002-4580-1114
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Paredes, Roger|||0000-0002-6553-691X
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Chamorro, Anna
  • Toledo, Ruth
  • Massanella, Marta|||0000-0002-3326-151X
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
To understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a prospective cohort of 332 patients with coronavirus disease 2019 (COVID-19) over more than a year after symptom onset. We evaluate plasma-neutralizing activity using HIV-based pseudoviruses expressing the spike of different SARS-CoV-2 variants and analyze them longitudinally using mixed-effects models. Long-term neutralizing activity is stable beyond 1 year after infection in mild/asymptomatic and hospitalized participants. However, longitudinal models suggest that hospitalized individuals generate both short- and long-lived memory B cells, while the responses of non-hospitalized individuals are dominated by long-lived B cells. In both groups, vaccination boosts responses to natural infection. Long-term (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice

  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Romero-Durana, Miguel|||0000-0001-6779-8553
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Avila-Nieto, Carlos
  • Pérez, Mónica
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Andrés, Cristina|||0000-0002-3200-0895
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Guallar, Victor|||0000-0002-4580-1114
  • Lepore, Rosalba
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Urrea, Víctor|||0000-0002-2577-856X
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Blanco, Julià|||0000-0002-2225-0217
The emerging SARS-CoV-2 variants of concern (VOCs) may display enhanced transmissibility, more severity and/or immune evasion; however, the pathogenesis of these new VOCs in experimental SARS-CoV-2 models or the potential infection of other animal species is not completely understood. Here we infected K18-hACE2 transgenic mice with B.1, B.1.351/Beta, B.1.617.2/Delta and BA.1.1/Omicron isolates and demonstrated heterogeneous infectivity and pathogenesis. B.1.351/Beta variant was the most pathogenic, while BA.1.1/Omicron led to lower viral RNA in the absence of major visible clinical signs. In parallel, we infected wildtype (WT) mice and confirmed that, contrary to B.1 and B.1.617.2/Delta, B.1.351/Beta and BA.1.1/Omicron can infect them. Infection in WT mice coursed without major clinical signs and viral RNA was transient and undetectable in the lungs by day 7 post-infection. In silico modeling supported these findings by predicting B.1.351/Beta receptor binding domain (RBD) mutations result in an increased affinity for both human and murine ACE2 receptors, while BA.1/Omicron RBD mutations only show increased affinity for murine ACE2.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection, A Case Report

  • Massanella, Marta|||0000-0002-3326-151X
  • Martin-Urda, Anabel
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Marín, Toni
  • Aldas Criado, Irene|||0000-0001-9291-873X
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Kipelainen, Athina
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Avila-Nieto, Carlos
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Rodon, Jordi|||0000-0002-1032-9091
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Parera, Mariona|||0000-0002-0756-8307
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
  • Prado, Julia G.|||0000-0002-5439-4645
  • Ballana, Ester|||0000-0002-5215-7363
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Masabeu, Àngels
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Toda, Maria de la Roca
  • Paredes, Roger|||0000-0002-6553-691X
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections have been reported; however, most cases are milder than the primary infection. We report the first case of a life-threatening critical presentation of a SARS-CoV-2 reinfection. A 62-year-old man from Palamós (Spain) suffered a first mild coronavirus disease 2019 (COVID-19) episode in March 2020, confirmed by 2 independent SARS-CoV-2 nasopharyngeal polymerase chain reaction (PCR) assays and a normal radiograph. He recovered completely and tested negative on 2 consecutive PCRs. In August 2020, the patient developed a second SARS-CoV-2 infection with life-threatening bilateral pneumonia and Acute respiratory distress syndrome criteria, requiring COVID-19-specific treatment (remdesivir + dexamethasone) plus high-flow oxygen therapy. Nasopharyngeal swabs from the second episode were obtained for virus quantification by real-time PCR, for virus outgrowth and sequencing. In addition, plasma and peripheral blood mononuclear cells during the hospitalization period were used to determine SARS-CoV-2-specific humoral and T-cell responses. Genomic analysis of SARS-CoV-2 showed that the virus had probably originated shortly before symptom onset. When the reinfection occurred, the subject showed a weak immune response, with marginal humoral and specific T-cell responses against SARS-CoV-2. All antibody isotypes tested as well as SARS-CoV-2 neutralizing antibodies increased sharply after day 8 postsymptoms. A slight increase of T-cell responses was observed at day 19 after symptom onset. The reinfection was firmly documented and occurred in the absence of robust preexisting humoral and cellular immunity. SARS-CoV-2 immunity in some subjects is unprotective and/or short-lived; therefore, SARS-CoV-2 vaccine schedules inducing long-term immunity will be required to bring the pandemic under control.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Bracke Manzanares, Carmen|||0000-0002-0306-8321
  • Avila-Nieto, Carlos
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Miranda, Cristina
  • González, Sandra
  • Toledo, Ruth
  • Font, Marta
  • Benet, Susana|||0000-0002-2219-8826
  • Escribà, Tuixent|||0000-0001-9467-7802
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Peña, Ruth
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Prado, Julia G.|||0000-0002-5439-4645
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Massanella, Marta|||0000-0002-3326-151X
  • Benítez Díaz, Rosa María|||0000-0001-6972-6094
  • Romero, Alba
  • Molina-Morant, Daniel|||0000-0002-4102-1065
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Pedro Botet, Maria Luisa|||0000-0001-7252-3191
  • Carrillo, Jorge|||0000-0003-0221-5948
Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n=9), common variable immunodeficiency (CVID, n=12), combined immunodeficiency (CID, n=1), and thymoma with immunodeficiency (TID, n=1). unPAD patients and healthy controls (HCs, n=10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Interestingly, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+ T cells. CID and TID patients developed cellular but not humoral responses. While the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses

  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Urrea, Víctor|||0000-0002-2577-856X
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Blanco, Pau
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Molinos-Albert, Luis Manuel|||0000-0001-5447-6803
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Avila-Nieto, Carlos
  • Varela, Ismael|||0000-0002-3825-372X
  • Cervera Gracia, Laura|||0000-0002-3639-2793
  • Gutiérrez-Granados, Sònia
  • Segura, Maria Mercedes
  • Gòdia, Francesc|||0000-0002-4060-9887
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing the antigen density on the surface of VLPs. In this work, we report an HIV-1 Gag-based VLP platform engineered to maximise the presence of antigen on the VLP surface. An HIV-1 gp41-derived protein (Min), including the C-terminal part of gp41 and the transmembrane domain, was fused to HIV-1 Gag. This resulted in high-density MinGag-VLPs. These VLPs demonstrated to be highly immunogenic in animal models using either a homologous (VLP) or heterologous (DNA/VLP) vaccination regimen, with the latter yielding 10-fold higher anti-Gag and anti-Min antibody titres. Despite these strong humoral responses, immunisation with MinGag-VLPs did not induce neutralising antibodies. Nevertheless, antibodies were predominantly of an IgG2b/IgG2c profile and could efficiently bind CD16-2. Furthermore, we demonstrated that MinGag-VLP vaccination could mediate a functional effect and halt the progression of a Min-expressing tumour cell line in an in vivo mouse model.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Syphilis vaccine, challenges, controversies and opportunities

  • Avila-Nieto, Carlos
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Mitjà, Oriol|||0000-0003-3266-8868
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
  • Carrillo, Jorge|||0000-0003-0221-5948
Syphilis is a sexually or vertically (mother to fetus) transmitted disease caused by the infection of Treponema pallidum subspecie pallidum (TPA). The incidence of syphilis has increased over the past years despite the fact that this bacterium is an obligate human pathogen, the infection route is well known, and the disease can be successfully treated with penicillin. As complementary measures to preventive campaigns and early treatment of infected individuals, development of a syphilis vaccine may be crucial for controlling disease spread and/or severity, particularly in countries where the effectiveness of the aforementioned measures is limited. In the last century, several vaccine prototypes have been tested in preclinical studies, mainly in rabbits. While none of them provided protection against infection, some prototypes prevented bacteria from disseminating to distal organs, attenuated lesion development, and accelerated their healing. In spite of these promising results, there is still some controversy regarding the identification of vaccine candidates and the characteristics of a syphilis-protective immune response. In this review, we describe what is known about TPA immune response, and the main mechanisms used by this pathogen to evade it. Moreover, we emphasize the importance of integrating this knowledge, in conjunction with the characterization of outer membrane proteins (OMPs), to expedite the development of a syphilis vaccine that can protect against TPA infection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities

  • Trigueros Peña, Macedonia|||0000-0003-4156-1018
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Palacín, Dolors
  • Muñoz-López, Francisco|||0000-0003-1789-1658
  • Avila-Nieto, Carlos
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Isnard, Mar|||0000-0001-6297-8520
  • Moreno, Nemesio|||0000-0002-1617-9549
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Puig Oliva, Teresa
  • Grau, Eulàlia|||0000-0002-2442-9165
  • Chamorro, Anna
  • Martinez, Ana
  • Toledo, Ruth
  • Font, Marta
  • Ara del Rey, Jordi|||0000-0002-7281-9969
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Prat, Nuria
  • Massanella, Marta|||0000-0002-3326-151X
SARS-CoV-2 vaccination is the most effective strategy to protect older residents of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses are less effective in older adults. Here, we characterised the humoral responses of institutionalised seniors 3 months after they had received the mRNA/BNT162b2 vaccine. plasma levels of SARS-CoV-2-specific total IgG, IgM and IgA antibodies were measured before and 3 months after vaccination in older residents of LTCF. Neutralisation capacity was assessed in a pseudovirus neutralisation assay against the original WH1 and later B.1.617.2/Delta variants. A group of younger adults was used as a reference group. three months after vaccination, uninfected older adults presented reduced SARS-CoV-2-specific IgG levels and a significantly lower neutralisation capacity against the WH1 and Delta variants compared with vaccinated uninfected younger individuals. In contrast, COVID-19-recovered older adults showed significantly higher SARS-CoV-2-specific IgG levels after vaccination than their younger counterparts, whereas showing similar neutralisation activity against the WH1 virus and an increased neutralisation capacity against the Delta variant. Although, similarly to younger individuals, previously infected older adults elicit potent cross-reactive immune responses, higher quantities of SARS-CoV-2-specific IgG antibodies are required to reach the same neutralisation levels. although hybrid immunity seems to be active in previously infected older adults 3 months after mRNA/BNT162b2 vaccination, humoral immune responses are diminished in COVID-19 uninfected but vaccinated older residents of LTCF. These results suggest that a vaccine booster dose should be prioritised for this particularly vulnerable population.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

  • Avila-Nieto, Carlos
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Brustolin, Marco|||0000-0002-3594-4488
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Rodon, Jordi|||0000-0002-1032-9091
  • Urrea, Víctor|||0000-0002-2577-856X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Ballana, Ester|||0000-0002-5215-7363
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Carabelli, Julieta|||0000-0003-2329-3996
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Guallar, Victor|||0000-0002-4580-1114
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Carrillo, Jorge|||0000-0003-0221-5948
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related. Nevertheless, S-2P still shows some molecular instability and it is produced with low yield. Here we described a novel set of mutations identified by molecular modeling and located in the S2 region of the S-2P that increase its production up to five-fold. Besides their immunogenicity, the efficacy of two representative S-2P-based mutants, S-29 and S-21, protecting from a heterologous SARS-CoV-2 Beta variant challenge was assayed in K18-hACE2 mice (an animal model of severe SARS-CoV-2 disease) and golden Syrian hamsters (GSH) (a moderate disease model). S-21 induced higher level of WH1 and Delta variants neutralizing antibodies than S-2P in K18-hACE2 mice three days after challenge. Viral load in nasal turbinate and oropharyngeal samples were reduced in S-21 and S-29 vaccinated mice. Despite that, only the S-29 protein protected 100% of K18-hACE2 mice from severe disease. When GSH were analyzed, all immunized animals were protected from disease development irrespectively of the immunogen they received. Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S-29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

  • Avila-Nieto, Carlos
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Brustolin, Marco|||0000-0002-3594-4488
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Rodon, Jordi|||0000-0002-1032-9091
  • Urrea, Víctor|||0000-0002-2577-856X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Ballana, Ester|||0000-0002-5215-7363
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Blanco, Julià|||0000-0002-2225-0217
  • Guallar, Victor|||0000-0002-4580-1114
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Carrillo, Jorge|||0000-0003-0221-5948
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18-hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development. In this study, the authors report a mutation that increases the production of recombinant SARS-CoV-2 Spike and exposure of the RBD. In animal models, a Spike-based vaccine containing the mutation induces strong immunogenicity, provides protection from disease and results in faster tissue viral clearance.